Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced new long-term data highlighting the sustained survival benefits of KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 ...
Mohs microscopic surgery and image-guided superficial radiation therapy (IG-SRT) demonstrate high local cure rates in the management of non-melanoma skin cancer.
For patients with diabetes and early-stage pulmonary malignancies, administration of a sodium-glucose cotransporter 2 ...
The combination of pembrolizumab and EVX-01, a personalized peptide-based neoantigen cancer vaccine, demonstrated activity in patients with advanced melanoma, according to phase 2 study results.
The concept of adjuvant therapy for cancer was developed at a time when systemic cancer treatment was limited to cytotoxic chemotherapy that could only be administered intermittently but rarely ...
New research published in Cell finds the existence of craters on the surface of melanoma cells that serve as immune hubs, ...
Prevention is always better than cure, particularly with potentially life-threatening diseases. But when dealing with an ...
Vaccination has emerged recently as a 'powerful frontier' in the development of effective cancer therapies by training immune ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback